Loading
TT
Tyme Technologies, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Van Tornout Jan M, was filed 22 Feb 2022.
Tyme Technologies, Inc.: what insiders have been doing
Every trade that managers of Tyme Technologies, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. No insider at Tyme Technologies, Inc. has published a filing in the past twelve months. The most recent one dates from 16 September 2022.
Looking back to 2021, when coverage begins, insiders filed 8 purchases and 90 sales.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
106
Thresholds
n/a
Buy Volume
€83,647
8 ops. · all time
Sell Volume
€2M
90 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended March 2022 · cache
Income statement
Net income-US$20.3M
Last declaration on 16 September 2022
Declarations106 total
10,000 sharesCommon StockSEC:0000899243-22-031353:0
5,865 sharesCommon StockSEC:0000899243-22-031355:0
105,000 sharesCommon StockSEC:0000899243-22-031347:0
20,022,566 sharesCommon StockSEC:0000899243-22-031354:0
110,000 sharesCommon StockSEC:0000899243-22-031352:0
258,300 sharesCommon StockSEC:0000899243-22-031350:0
5,865 sharesCommon StockSEC:0000899243-22-031351:0
100,000 sharesCommon StockSEC:0000899243-22-031345:0
80,000 shares@ US$0.26382.3% of flowCommon StockSEC:0001712467-22-000027:0
80,000 shares@ US$0.29292.5% of flowCommon StockSEC:0001712467-22-000026:0
70,000 shares@ US$0.29172.1% of flowCommon StockSEC:0001712467-22-000025:0
70,000 shares@ US$0.2862.1% of flowCommon StockSEC:0001712467-22-000024:0
60,000 shares@ US$0.26791.6% of flowCommon StockSEC:0001712467-22-000023:0
60,000 shares@ US$0.26221.6% of flowCommon StockSEC:0001712467-22-000022:0
78,125 shares@ US$0.261.4% of flowCommon StockSEC:0000899243-22-023739:0
60,000 shares@ US$0.25091.5% of flowCommon StockSEC:0001712467-22-000021:0
78,125 shares@ US$0.271.4% of flowCommon StockSEC:0000899243-22-022002:0
53,097 shares@ US$0.25061.3% of flowCommon StockSEC:0001712467-22-000020:0
78,125 shares@ US$0.241.3% of flowCommon StockSEC:0000899243-22-019922:0
50,000 shares@ US$0.25011.3% of flowCommon StockSEC:0001712467-22-000018:0
50,000 shares@ US$0.25081.3% of flowCommon StockSEC:0001712467-22-000019:0
78,125 shares@ US$0.311.7% of flowCommon StockSEC:0000899243-22-017633:0
50,000 shares@ US$0.31391.6% of flowCommon StockSEC:0001712467-22-000017:0
78,125 shares@ US$0.321.7% of flowCommon StockSEC:0000899243-22-016026:0
40,000 shares@ US$0.32351.3% of flowCommon StockSEC:0001712467-22-000016:0
25 of 106 declarations
About Tyme Technologies, Inc.
TYME TECHNOLOGIES, INC. (ticker: TYME) is a US-listed company traded on the NASDAQ in the United States. For investors, it fits the profile of a small-cap biotech, historically focused on oncology and cancer-metabolism-based therapies. TYME Technologies was organized in Delaware and for much of its public-company history was headquartered in New York; more recent SEC materials identify a Bedminster, New Jersey business address. The company’s common stock has traded on the Nasdaq Capital Market since July 2017, reinforcing its place in the high-risk, growth-oriented segment of the US equity market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537917/000156459020026661/tyme-10k_20200331.htm?utm_source=openai))
Operationally, TYME described itself as an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs) intended to address a broad range of solid tumors and hematologic cancers. That makes the company fundamentally different from a commercial-stage pharmaceutical group: its value proposition has been tied primarily to preclinical and clinical development milestones, regulatory progress, and access to capital rather than recurring product revenue. In other words, the investment case has been driven by scientific optionality and binary event risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1556263/000119312522187527/d339682dex991.htm?utm_source=openai))
Read moreShow less
From a corporate-history perspective, TYME’s roots go back to a restructuring and reverse-merger era in the mid-2010s, with earlier corporate activity linked to the formation of the underlying entity in 2011 and later reorganization into the current public structure. This background matters for analysts because it highlights a company that has evolved through capital-market events and strategic repositioning rather than through a long history of scaled commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537917/000116169717000284/form_10-k.htm?utm_source=openai))
TYME’s competitive position has always been that of a niche oncology developer operating in a crowded field. Its therapeutic thesis centered on tumor-metabolism targeting and the possibility of relatively low-toxicity treatment options that could preserve patients’ quality of life. That differentiation is scientifically attractive, but in biotech investing it must be weighed against execution risk, clinical trial uncertainty, and ongoing financing needs. As a result, TYME has typically been viewed as a speculative small-cap name rather than a diversified healthcare platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1556263/000119312522187527/d339682dex991.htm?utm_source=openai))
Recent company news has suggested a strategic review posture rather than a straightforward operating-growth story. SEC-linked materials from 2022 indicate TYME initiated a formal process with Moelis & Company, signaling that management was evaluating strategic alternatives and potential value-maximizing transactions. For Form 4 insider-transaction readers, this is an important context point: insider activity in TYME should be interpreted against the backdrop of a company whose future has been closely tied to capital markets, strategic options, and the outcome of its oncology pipeline. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537917/000119312522087374/d282410dex991.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
